Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Venner

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Equine Veterinary Journal|December 15, 2017
Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foalsS Berlin, S Wallstabe, E Scheuch, et al.
Seminars in Oncology|April 1, 1988
Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostateP M Venner, P G Klotz, L H Klotz, et al.
The Canadian Journal of Urology|May 10, 2005
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centresD Scott Ernst, Penny Brasher, Peter M Venner, et al.
Cancer Research|November 1, 1981
Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemiaP M Venner, R I Glazer, J Blatt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and painD S Ernst, I F Tannock, E W Winquist, et al.
British Journal of Haematology|September 21, 2006
High dose calcitriol may reduce thrombosis in cancer patientsTomasz M Beer, Peter M Venner, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancerAnthony W Tolcher, Leonard Reyno, Peter M Venner, et al.
Cancer|October 27, 2007
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcomaVivien H C Bramwell, Donald Morris, D Scott Ernst, et al.
Urology|September 25, 1997
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Equine Veterinary Journal|December 15, 2017
Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foalsS Berlin, S Wallstabe, E Scheuch, et al.
Seminars in Oncology|April 1, 1988
Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostateP M Venner, P G Klotz, L H Klotz, et al.
The Canadian Journal of Urology|May 10, 2005
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centresD Scott Ernst, Penny Brasher, Peter M Venner, et al.
Cancer Research|November 1, 1981
Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemiaP M Venner, R I Glazer, J Blatt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and painD S Ernst, I F Tannock, E W Winquist, et al.
British Journal of Haematology|September 21, 2006
High dose calcitriol may reduce thrombosis in cancer patientsTomasz M Beer, Peter M Venner, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2002
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancerAnthony W Tolcher, Leonard Reyno, Peter M Venner, et al.
Cancer|October 27, 2007
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2002
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcomaVivien H C Bramwell, Donald Morris, D Scott Ernst, et al.
Urology|September 25, 1997
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Pageof 10